HIGHLIGHTS
- who: Zhenshu Xu et al. from the Division of and Oncology, Valhalla, NY, USA Medical University, Fuzhou, China have published the Article: Hematology Reviews 2009; volume 1:e4, in the Journal: (JOURNAL)
- what: Although rare, severe CHF and left ventricular dysfunction have occurred with imatinib treatment, especially in patients receiving higher doses.
- future: Research is needed to clarify the mechanisms underlying these effects.
SUMMARY
In the IRIS study, anemia, neutropenia, and thrombocytopenia (all grades) were each reported by 45-61% of patients receiving imatinib. The updated dasatinib label includes . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.